Company: CRLBF
Filing Date: 2025-09-18
Form Type: SC TO-I/A
Source: 0001832928-25-000026
Chunk: 0

Company: Cresco Labs Inc.
Filing Date: 2025-09-18
Form: SC TO-I/A
Chunk 0
---
### UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### SCHEDULE TO/A
<div align='center'>(Amendment No. 1) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF
THE SECURITIES EXCHANGE ACT OF 1934</div>

#### Cresco Labs Inc.
<div align='center'>(Name of Subject Company (Issuer))</div>

#### Cresco Labs Inc., as Issuer and Offeror
<div align='center'>(Name of Filing Persons (Identifying status as offeror, issuer, or other person))

Options to purchase subordinate voting shares, no par value per share
(Title of Class of Securities)

CA22587M1068 for the subordinate voting shares
(CUSIP Number of Class of Securities)

John Schetz
Cresco Labs Inc.
600 West Fulton Street, Suite 800
Chicago, IL 60661
(312) 929-0993

(Name, address and telephone number of person authorized to receive notices and communications on behalf of filing persons)

Copy to:

Heidi Steele
McDermott Will & Schulte LLP
444 West Lake Street, Suite 4000
Chicago, IL 60606
(312) 372-2000</div>

☐ Check the box if filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

☐ third-party tender offer subject to Rule 14d-1.

☒ issuer tender offer subject to Rule 13e-4.

☐ going-private transaction subject to Rule 13e-3.

☐ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☒

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

This Amendment to the Tender Offer Statement on Schedule TO (this “ Amendment ”) amends and supplements the Tender Offer Statement on Schedule TO filed with the U.S. Securities and Exchange Commission on August 20, 2025 (together with its exhibits, the “ Schedule